> Detailanzeige

Chu, Carissa; Alshalalfa, Mohammed; Sjöström, Martin; Zhao, Shuang; Herlemann, Annika; Chou, Jonathan; Mahal, Brandon Arvin Virgil; Kishan, Amar Upadhyaya; Spratt, Daniel Eidelberg; Karnes, Jeffrey; Small, Eric Jay; Wong, Anthony C.; Porten, Sima P.; Hope, Thomas; Davicioni, Elai; Nguyen, Paul L.; Carroll, Peter; Schaeffer, Edward M.; Feng, Felix Y; Cooperberg, Matthew R.

Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer
  • Beteiligte: Chu, Carissa; Alshalalfa, Mohammed; Sjöström, Martin; Zhao, Shuang; Herlemann, Annika; Chou, Jonathan; Mahal, Brandon Arvin Virgil; Kishan, Amar Upadhyaya; Spratt, Daniel Eidelberg; Karnes, Jeffrey; Small, Eric Jay; Wong, Anthony C.; Porten, Sima P.; Hope, Thomas; Davicioni, Elai; Nguyen, Paul L.; Carroll, Peter; Schaeffer, Edward M.; Feng, Felix Y; Cooperberg, Matthew R.
  • Erschienen: American Society of Clinical Oncology (ASCO), 2020
  • Erschienen in: Journal of Clinical Oncology
  • Sprache: Englisch
  • DOI: 10.1200/jco.2020.38.6_suppl.295
  • ISSN: 0732-183X; 1527-7755
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> 295 </jats:p><jats:p> Background: While <jats:sup>18</jats:sup>F-fluciclovine PET/CT is approved in the US and recommended by the NCCN, prostate-specific membrane antigen (PSMA) PET/CT is more common in Europe/Australia and recommended by the EAU. Less is known about the biology of lesions detected by either modality. <jats:sup>18</jats:sup>F-fluciclovine PET relies on radiotracer uptake by amino acid transporters LAT1-4 and ASCT1-2. PSMA PET is dependent on surface expression of PSMA. We compared relative expression of PSMA and fluciclovine transporter genes in radical prostatectomy (RP) samples to determine their distribution across subtypes and correlation with outcomes. Methods: Gene expression data of 19,102 RP samples were analyzed using the Affymetrix Human Exon 1.0 ST microarray. 1,135 patients had long term follow up. Associations between expression of PSMA and fluciclovine transporter genes (LAT1-4 and ASCT1-2) and pathologic variables, molecular subtypes, and clinical outcomes were conducted. Results: All fluciclovine transporter genes (LAT 1-4, ASCT1-2) were expressed at lower levels than PSMA (p &lt;0.0001). PSMA expression was positively correlated with genomic risk score and pathologic Gleason score (p&lt;0.0001), but LAT2-3 and ASCT2 were inversely correlated with genomic risk in primary tumors (p&lt;0.0001) and less expressed in GS 9-10 tumors (p&lt;0.0001). PSMA expression was associated with worse metastasis-free survival (MFS) (HR 1.45, p=0.001) and lymph node involvement (HR 2.14, p&lt;0.0001). Expression of LAT2, LAT3, ASCT2 expression was associated with better MFS (HR 0.85, 0.63, 0.74, p&lt;0.0001-0.04). After multivariable adjustment, PSMA expression remained independently prognostic of poorer MFS (HR 1.3, p=0.028). Luminal B subtype was notable for PSMA overexpression; Luminal A was enriched in ASCT2 and LAT2 (p&lt;0.0001). PSMA expression did not correlate with ERG fusion prostate cancers, but LAT2, ASCT1, and ASCT2 were overexpressed in ERG fusion negative tumors (p&lt;0.0001). Conclusions: PSMA expression is associated with more aggressive disease and poorer clinical outcomes than fluciclovine transporter genes in localized prostate cancer. Molecular subtypes of prostate cancer vary in PSMA and fluciclovine transporter gene expression. </jats:p>
  • Zugangsstatus: Freier Zugang